ArticleJournal for immunotherapy of cancer2019
Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells.
Article in Journal for immunotherapy of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Cholangiocarcinoma:Unveiling the cold tumor microenvironment and strategies for immune rejuvenation.Oncogene · 2026Review
- LDHA-driven lactate metabolism promotes MDSC activation and immunosuppressive microenvironment in prostate cancer.Oncogene · 2026Article
- A comprehensive review of mechanisms underlying resistance to immune checkpoint inhibitors.Frontiers in immunology · 2026Review
- Combined elevation of myeloid-derived suppressor cells and Tregs predicts lymph node metastasis in breast cancer.BMC cancer · 2025Article
- Multi-omics analysis identifies an M-MDSC-like immunosuppressive phenotype in lineage-switched AML with KMT2A rearrangement.Nature communications · 2025Article
- Review
- Abnormal proportions and functions of myeloid-derived suppressor cells in peripheral blood of patients with diffuse large B-cell lymphoma.BMC cancer · 2025Article
- The Dynamic Changes of Circulating Myeloid-Derived Suppressor Cells (MDSCs) Subsets in Colorectal Cancer Patients Undergoing Oxaliplatin-Based Chemotherapy.Journal of gastrointestinal cancer · 2025Article
- A Pilot Study Assessing the Utility of Quantitative Myeloid-Derived Suppressor Cell Measurements in Detecting Posttraumatic Infection.Critical care explorations · 2025Observational
- CD16 and Siglec expression refine the phenotypic heterogeneity of steady-state myeloid-derived suppressor cells.Frontiers in oncology · 2025Article
- Pharmacological and genetic inhibition of ARG2 in CXCR2Theranostics · 2025Article
- Myeloid-derived suppressor cells and T cell populations in children with Multisystem Inflammatory Syndrome.Pediatric research · 2024Observational
- Evaluating Leukocyte Telomere Length and Myeloid-Derived Suppressor Cells as Biomarkers for Prostate Cancer.Cancers · 2024Article
- Review
- Osteomyelitis is associated with increased anti-inflammatory response and immune exhaustion.Frontiers in immunology · 2024Article
- Myeloid-Derived Suppressor-Cell Dynamics Control Outcomes in the Metastatic Niche.Cancer immunology research · 2023Article
- Reduced Type 2 Innate Lymphocyte Cell Frequencies in PatentPathogens (Basel, Switzerland) · 2023Article
- Role of myeloid-derived suppressor cells in tumor recurrence.Cancer metastasis reviews · 2023Review
- Immune State Conversion of the Mesenteric Lymph Node in a Mouse Breast Cancer Model.International journal of molecular sciences · 2022Article
- New Perspectives on Myeloid-Derived Suppressor Cells and Their Emerging Role in Haematology.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyeloid-derived suppressor cells (MDSC) have been found to play an important role in limiting immune responses in cancer. Higher circulating MDSC levels have been associated with greater tumor burden, poorer response to immunotherapy, and poorer survival. Optimal measurement of MDSC levels could provide clinicians with a useful prognostic and/or management tool.
methodsA whole blood (WB) nine color, 11 parameter flow cytometric assay was designed, utilizing fluorescently-labeled antibodies against CD45, CD3, CD19, CD20, CD56, CD16, HLA-DR, CD33, CD11b, CD14 and CD15, and BD Trucount beads for quantitation. Total MDSC were defined as CD45 + CD3
resultsA novel gating strategy was devised to eliminate granulocytes and improve consistency in gating. Several pre-analytical variables were found to significantly affect MDSC quantitation, including collection tube type and time elapsed between blood collection and testing. Total and M-MDSC levels were a mean of 63% and 73% greater, respectively, with K
conclusionsMDSC are a heterogenous group of cells, and their quantitation in WB can be affected by a number of pre-analytical variables. Consideration of these factors, and measurement using a material type that has not been manipulated, such as whole blood, is likely to yield the most accurate results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.